TCOV
CASI

Trust Company of Vermont’s CASI Pharmaceuticals CASI Stock Holding History

Trust Company of Vermont’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10
Closed -$28 – 1044
2024
Q4 		$28 Hold
10
– – ﹤0.01% 1046
2024
Q3 		$62 Hold
10
– – ﹤0.01% 1052
2024
Q2 		$55 Buy
+10
New +$31 ﹤0.01% 894

Other funds holding CASI

FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Trust Company of Vermont's CASI Position: Q1 2025 in Review

Trust Company of Vermont sold out of CASI Pharmaceuticals (CASI) in Q1 2025, closing a stake of 10 shares — an estimated $28 sold.

Trust Company of Vermont first reported a position in CASI in Q2 2024 and held it in 3 quarters. The position peaked at $62 in Q3 2024. 23 funds tracked by Wall St. Rank hold CASI as of Q1 2025.

  • Trust Company of Vermont reported no remaining CASI Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Trust Company of Vermont sold 10 CASI Pharmaceuticals shares in Q1 2025, an estimated $28.
  • Trust Company of Vermont first reported a position in CASI Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • Trust Company of Vermont's CASI Pharmaceuticals position peaked at $62 in Q3 2024.
  • 23 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q1 2025.

Based on Trust Company of Vermont's 13F filing for Q1 2025, filed 24 Apr 2025.